ClinicalTrials.gg
CompletedNCT03976375Updated Aug 15, 2025Results posted

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

A Phase 3 interventional study of Pembrolizumab and Lenvatinib in Metastatic Non-Small Cell Lung Cancer, sponsored by Merck Sharp & Dohme LLC. Completed at 143 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-15.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
422
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung — 29 open to participants now, 48 under way, 13 of them phase 3. pembrolizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
19th of 127
422 · median 65
Started
2019
with 7 others
Phase 3
28 of 127
4 open now
Registered
66th of 127
by date
Lead sponsor
27 of 127
Merck Sharp & Dohme LLC

Among the 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung, this one is the 19th largest by enrollment, is one of 8 that started in 2019, is one of 28 in phase 3, and was the 66th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

29 of the 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung are open now, in 10 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of pembrolizumab (MK-3475) with lenvatinib (E7080/MK-7902) vs. docetaxel in participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and treatment with one prior anti-PD-1/PD-L1 monoclonal antibody (mAb). The primary hypotheses of this study are that pembrolizumab + lenvatinib (compared with docetaxel) prolongs: 1) overall survival (OS); and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review (BICR).

03

Conditions studied

  • Metastatic Non-Small Cell Lung Cancer

Keywords

  • programmed cell death 1 (PD-1, PD1)
  • programmed cell death-ligand 1 (PD-L1, PDL1)
  • programmed cell death-ligand 2 (PD-L2, PDL2)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a or cytologically confirmed diagnosis of squamous or nonsquamous Non-Small Cell Lung Cancer (NSCLC) -Stage IV: M1a, M1b, M1c.
  • Has progressive disease (PD) on treatment with one prior anti-programmed cell death 1 ()/programmed cell death ligand 1 (PD-L1) monoclonal antibody (mAb) administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies.

    • Retreatment with the same anti-PD-L1/PD-L1 mAb is acceptable in the overall course of treatment
  • Has PD during/after platinum doublet chemotherapy for metastatic disease.
  • Has confirmation that EGFR-, ALK-, or ROS1-directed therapy is not indicated as primary therapy (documentation of absence of tumor-activating EGFR mutations [eg, DEL19 or L858R], and absence of ALK and ROS1 gene rearrangements OR presence of a K-ras mutation).
  • Has submitted pre-study imaging that confirmed evidence of PD following initiation of an anti-PD-1/PD-L1 inhibitor.
  • Has at least 1 by computerized tomography (CT) or magnetic resonance imaging (MRI) per (RECIST) 1.1, as determined by the local site assessment.
  • Has provided tumor tissue for PD-L1 biomarker analysis from an (defined as: from initial diagnosis of NSCLC and prior to receiving immunotherapy [antiPD-1/PD-L1], from the primary lesion or a metastatic lesion).
  • Has provided prior to allocation tissue from a newly obtained formalin-fixed sample from a new biopsy (defined as: after completion of immunotherapy [anti-PD-1/PD-L1] and before receiving a randomization number), of a tumor lesion not previously irradiated.
  • Has (ECOG) performance status of 0 or 1 within 7 days before the first dose of study intervention but before randomization.
  • Has a of at least 3 months.
  • Male participants receiving pembrolizumab ± lenvatinib or lenvatinib must agree to refrain from donating sperm, and either 1) be abstinent from heterosexual intercourse; or 2) follow guidance during the treatment period or 7 days after the last dose of lenvatinib. Male participants receiving docetaxel agree to adhere to the same conditions during the treatment period and for ≥90 days after the last dose of study treatment.
  • Female participants must not be pregnant, not be breastfeeding, and not be a woman of (WOCBP). If a WOCBP, agrees to not donate eggs and either use contraception, or be abstinent from heterosexual intercourse during the treatment period and for ≥120 days after the last dose of pembrolizumab or 30 days after the last dose of lenvatinib, whichever occurs last. If a WOCBP receiving docetaxel, agrees to adhere to the same conditions during the treatment period and for ≥30 days after the last dose of study treatment.
  • Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤150/90 mm Hg and no change in antihypertensive medications within 1 week before randomization.
  • If participant received major surgery or radiation therapy of >30 Gy, they have recovered from the toxicity and/or complications from the intervention.
  • Has adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Has received docetaxel as monotherapy or in combination with other therapies.
  • Has received lenvatinib as monotherapy or in combination with an /PD-L1 mAb.
  • Has received: 1) radiotherapy within 2 weeks before the first dose of study treatment; or 2) lung radiation therapy >30 Gy within 6 months before the first dose of study treatment.
  • Has received a within 30 days before the first dose of study treatment.
  • Has hemoptysis or tumor bleeding within 2 weeks before the first dose of study treatment.
  • Has radiographic evidence of intratumoral cavitation, encasement, or invasion of a major blood vessel.
  • Has clinically significant cardiovascular impairment within 12 months of the first dose of study treatment.
  • Has a history of a gastrointestinal condition or procedure that may affect oral absorption of study treatment.
  • Has a pre-existing ≥Grade 3 gastrointestinal or non-gastrointestinal fistula.
  • Is currently participating in a clinical trial and receiving study therapy or participated in a study of an agent within 4 weeks of the first dose of study treatment.
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy or any other form of therapy within 7 days before the first dose of study treatment.
  • Has a known history of an additional , except if the participant has undergone potentially curative therapy with no evidence of disease recurrence for 3 years since initiation of that therapy.
  • Has known active central nervous system and/or carcinomatous meningitis.
  • Has severe to pembrolizumab and/or any of its .
  • Has a sensitivity to any of the excipients contained in lenvatinib and/or docetaxel.
  • Has an active disease that has required systemic treatment in the past 2 years.
  • Has a history of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease.
  • Has an active infection requiring systemic therapy.
  • Has a known history of (HIV) infection.
  • Has a known history of reactive or known active virus infection.
  • Has active tuberculosis.
  • Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through at least 120 days after the last dose of pembrolizumab or lenvatinib, or 90 days (male participants) or 30 days (for female participants) after the last dose of docetaxel.
  • Has had an allogeneic tissue/solid organ transplant.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
422 participants (actual)

Study arms

  • Experimental
    Pembrolizumab+Lenvatinib

    Participants receive pembrolizumab at 200 mg, every 3 weeks (Q3W) via intravenous (IV) infusion on Day 1 of each 21-day cycle, in combination with lenvatinib at 20 mg, once daily (QD) via oral capsule. Pembrolizumab will be administered for up to 35 treatment cycles (\~2 years). Lenvantinib will be administered until progressive disease or unacceptable toxicity.

    Biological: Pembrolizumab · Drug: Lenvatinib

  • Active comparator
    Docetaxel

    Participants receive docetaxel at 75 mg/m\^2, Q3W via IV infusion over 1-hour infusion on Day 1 of each 21-day cycle. Docetaxel will be administered until progressive disease or unacceptable toxicity.

    Drug: Docetaxel

  • Experimental
    Lenvatinib Monotherapy

    Participants receive lenvatinib at 24 mg, QD via oral capsule. Lenvantinib will be administered until progressive disease or unacceptable toxicity.

    Drug: Lenvatinib

Interventions

  • BiologicalPembrolizumab

    IV infusion of pembrolizumab at 200 mg

    Also known as: MK-3475, KEYTRUDA®

  • Oral capsules (unit strength: 4 and 10 mg) at 20 mg or 24 mg total daily dose.

    Also known as: MK-7902, E7080, LENVIMA®

  • IV infusion of docetaxel at 75 mg/m\^2.

    Also known as: TAXOTERE®

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from randomization to the date of death due to any cause.

    Time frame: Up to ~47 months

  2. Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions is also considered PD. PFS was assessed by blinded independent central review (BICR) per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

    Time frame: Up to ~47 months

Secondary outcomes

  1. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+Lenvatinib vs. Docetaxel

    ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions). ORR was assessed by BICR per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

    Time frame: Up to ~47 months

  2. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+Lenvatinib vs. Lenvatinib Monotherapy

    ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions). ORR was assessed by BICR per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

    Time frame: Up to ~47 months

  3. Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    DOR is defined as the time from first documented evidence of Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) until disease progression or death due to any cause, whichever occurs first. DOR was assessed by BICR per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

    Time frame: Up to ~47 months

  4. Number of Participants Experiencing an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced an AE is presented.

    Time frame: Up to ~47 months

  5. Number of Participants Discontinuing Study Treatment Due to an AE

    The number of participants who discontinued study treatment due to an AE is presented.

    Time frame: Up to ~47 months

  6. Change From Baseline in European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Combined Global Health Status / Quality of Life (Items 29 & 30) Scale Combined Score

    The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the quality of life (QoL) of cancer patients, including a combined global health status (GHS)/QoL (Items 29 and 30) scale. For each item, scores range from 0-100, with higher scores indicating higher GHS/QoL. Per protocol, scores for items 29 and 30 will be averaged to compute a combined GHS/QoL scale score. Change from baseline in the combined GHS/QoL scale scores is presented.

    Time frame: Baseline and Week 12

  7. Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer Module 13 (QLQ-LC13) Cough (Item 31) Scale Score

    Used in combination with QLQ-C30, the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, including a single-item scale score for cough (Item 31). For this item, individual responses to the question "How much did you cough?" are given on a 4-point scale (1=Not at all; 4=Very much). Scores are transformed to a range from 0-100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-LC13 cough (Item 31) scale score is presented.

    Time frame: Baseline and Week 12

  8. Change From Baseline in EORTC QLQ-LC13 Chest Pain (Item 40) Scale Score

    Used in combination with QLQ-C30, the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, including a single-item scale score for chest pain (Item 40). For this item, individual responses to the question "Have you had pain in your chest?" are given on a 4-point scale (1=Not at all; 4=Very much). Scores are transformed to a range from 0-100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-LC13 chest pain (Item 40) scale score is presented.

    Time frame: Baseline and Week 12

  9. Change From Baseline in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score

    The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a single-item scale score for dyspnea (Item 8). For this item, individual responses to the question "Were you short of breath?" are given on a 4-point scale (1=Not at all; 4=Very much). Scores are transformed to a range from 0-100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-C30 dyspnea (Item 8) scale score is presented.

    Time frame: Baseline and Week 12

  10. Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Combined Score

    The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a physical functioning (PF) scale (Items 1 to 5). The PF scale consists of participant responses to 5 questions regarding performance of daily activities \[1) strenuous activities; 2) long walks; 3) short walks; 4) bed/chair rest; and 5) needing help with eating, dressing, washing themselves or using the toilet\]. Overall PF scores range from 0 to 100, with a lower score indicating a better outcome. The change from Baseline in the EORTC QLQ-C30 PF (Items 1 to 5) scale combined score is presented.

    Time frame: Baseline and Week 12

  11. Time to True Deterioration (TTD) in EORTC QLQ-C30 Combined Global Health Status / Quality of Life (Items 29 & 30) Scale Combined Score

    The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a combined GHS/QoL (Items 29 and 30) scale. The TTD in the combined GHS/QoL (Items 29 \& 30) scale combined score is presented, defined as the time to first onset of a ≥10 point decrease from baseline. A longer TTD indicates a better outcome

    Time frame: Up to 24 months

  12. Time to True Deterioration (TTD) in EORTC QLQ-LC13 Cough (Item 31) Scale Score

    Used in combination with QLQ-C30, the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, including a single-item scale score for cough (Item 31). The TTD in EORTC QLQ-LC13 cough (Item 31) scale score is presented, defined as the time to first onset of a ≥10 point decrease from baseline.

    Time frame: Up to ~24 months

  13. Time to True Deterioration (TTD) in EORTC QLQ-LC13 Chest Pain (Item 40) Scale Score

    Used in combination with QLQ-C30, the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, including a single-item scale score for chest pain (Item 40). The TTD in EORTC QLQ-LC13 chest pain (Item 40) scale score is presented, defined as the time to first onset of a ≥10 point decrease from baseline.

    Time frame: Up to ~24 months

  14. Time to True Deterioration (TTD) in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score

    The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a single-item scale score for dyspnea (Item 8). The TTD in dyspnea (Item 8) scale score will be presented, defined as the time to first onset of a ≥10 point decrease from baseline.

    Time frame: Up to ~24 months

  15. Time to True Deterioration (TTD) in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Combined Score

    The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a physical functioning (PF) scale (Items 1 to 5). The TTD in PF (Items 1 to 5) scale combined score is presented, defined as the time to first onset of a ≥10 point decrease from baseline.

    Time frame: Up to ~24 months

  16. Time to True Deterioration (TTD) in EORTC Composite Symptom Score for Cough (QLQ-LC13 Item 31), Chest Pain (QLQ-LC13 Item 40), or Dyspnea (QLQ-C30 Item 8)

    EORTC QLQ-C30 includes a single-item scale score for dyspnea (Item 8), the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, which includes a single-item scale score for cough (Item 31) and chest pain (Item 40). Time to True Deterioration for the Composite Endpoint of EORTC QLQ- LC13 Cough, EORTC QLQ- LC13 Chest Pain, or EORTC QLQ-C30 Dyspnea is presented, defined as the time to first onset of a ≥10-point decrease from baseline in any one of 3 scale items with confirmation by the subsequent visit of a 10 or more-point deterioration from baseline in the same scale as the first onset under right-censoring rule.

    Time frame: Up to ~ 24 months

07

Results

Posted Aug 22, 2024

Participant flow

Participant flow — Overall Study
MilestonePembrolizumab+LenvatinibDocetaxelLenvatinib
Started18518948
Treated18117747
Completed000
Not completed18518948
Withdrew: Death15816042
Withdrew: Lost to follow-up211
Withdrew: Withdrawal by subject594
Withdrew: Sponsor decision20191

Outcome measures

PrimaryOverall Survival (OS)

OS is defined as the time from randomization to the date of death due to any cause.

Time frame:
Up to ~47 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsPembrolizumab+LenvatinibDocetaxelLenvatinib Monotherapy
Overall Survival (OS)11.3 (9.4 to 13.2)12.0 (9.6 to 13.7)—
Statistical analysis
  • Pembrolizumab+Lenvatinib vs Docetaxel · Log Rank · p = 0.4342 (Stratified by Baseline ECOG performance status (0 versus 1), anti-PD-1/PD-L1 mAb (immediate prior therapy versus not the immediate prior therapy), and Baseline PD-L1 Status (\<50% versus \>=50)) · Hazard ratio (hr): 0.98 · 95% CI 0.78 to 1.23Based on stratified Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Baseline ECOG performance status, anti-PD-1/PD-L1 mAb therapy, and Baseline PD-L1 Status
PrimaryProgression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions is also considered PD. PFS was assessed by blinded independent central review (BICR) per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

Time frame:
Up to ~47 months
Reported as:
Median · Months
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
MonthsPembrolizumab+LenvatinibDocetaxelLenvatinib Monotherapy
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)5.6 (4.2 to 6.5)4.2 (3.2 to 5.2)—
Statistical analysis
  • Pembrolizumab+Lenvatinib vs Docetaxel · Log Rank · p = 0.1563 (Stratified by Baseline ECOG performance status (0 versus 1), anti-PD-1/PD-L1 mAb (immediate prior therapy versus not the immediate prior therapy), and Baseline PD-L1 Status (\<50% versus \>=50)) · Hazard ratio (hr): 0.89 · 95% CI 0.70 to 1.12Based on stratified Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Baseline ECOG performance status, anti-PD-1/PD-L1 mAb therapy, and Baseline PD-L1 Status.
SecondaryObjective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+Lenvatinib vs. Docetaxel

ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions). ORR was assessed by BICR per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

Time frame:
Up to ~47 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+Lenvatinib vs. Docetaxel
Percentage of ParticipantsPembrolizumab+LenvatinibDocetaxelLenvatinib Monotherapy
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+Lenvatinib vs. Docetaxel22.7 (16.9 to 29.4)14.3 (9.6 to 20.1)—
Statistical analysis
  • Pembrolizumab+Lenvatinib vs Docetaxel · Miettinen and Nurminen method · p = 0.01818 (One-sided p-value for testing. H0: difference in % =0 versus H1: difference in % \> 0.) · Difference in percentage vs docetaxel: 8.4 · 95% CI 0.5 to 16.3Based on Miettinen \& Nurminen method stratified by Baseline ECOG performance status (0 versus 1), anti-PD-1/PD-L1 mAb (immediate prior therapy versus not the immediate prior therapy), and Baseline PD-L1 Status (\<50% versus \>=50%)
SecondaryObjective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+Lenvatinib vs. Lenvatinib Monotherapy

ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions). ORR was assessed by BICR per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

Time frame:
Up to ~47 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+Lenvatinib vs. Lenvatinib Monotherapy
Percentage of ParticipantsPembrolizumab+LenvatinibLenvatinib MonotherapyDocetaxel
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+Lenvatinib vs. Lenvatinib Monotherapy22.7 (16.9 to 29.4)12.5 (4.7 to 25.2)—
Statistical analysis
  • Pembrolizumab+Lenvatinib vs Lenvatinib Monotherapy · Miettinen & Nurminen method · p = 0.06009 (One-sided p-value for testing. H0: difference in % =0 versus H1: difference in % \> 0.) · Difference in percentage vs lenvatinib: 10.2 · 95% CI -3.1 to 19.9
SecondaryDuration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

DOR is defined as the time from first documented evidence of Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) until disease progression or death due to any cause, whichever occurs first. DOR was assessed by BICR per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

Time frame:
Up to ~47 months
Reported as:
Median · Months
Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
MonthsPembrolizumab+LenvatinibDocetaxelLenvatinib Monotherapy
Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)6.9 (2.3 to NA)6.8 (NA to NA)—
SecondaryNumber of Participants Experiencing an Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced an AE is presented.

Time frame:
Up to ~47 months
Reported as:
Number · Participants
Number of Participants Experiencing an Adverse Event (AE)
ParticipantsPembrolizumab+LenvatinibDocetaxelLenvatinib Monotherapy
Number of Participants Experiencing an Adverse Event (AE)17917447
SecondaryNumber of Participants Discontinuing Study Treatment Due to an AE

The number of participants who discontinued study treatment due to an AE is presented.

Time frame:
Up to ~47 months
Reported as:
Number · Participants
Number of Participants Discontinuing Study Treatment Due to an AE
ParticipantsPembrolizumab+LenvatinibDocetaxelLenvatinib Monotherapy
Number of Participants Discontinuing Study Treatment Due to an AE684313
SecondaryChange From Baseline in European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Combined Global Health Status / Quality of Life (Items 29 & 30) Scale Combined Score

The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the quality of life (QoL) of cancer patients, including a combined global health status (GHS)/QoL (Items 29 and 30) scale. For each item, scores range from 0-100, with higher scores indicating higher GHS/QoL. Per protocol, scores for items 29 and 30 will be averaged to compute a combined GHS/QoL scale score. Change from baseline in the combined GHS/QoL scale scores is presented.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Combined Global Health Status / Quality of Life (Items 29 & 30) Scale Combined Score
Scores on a scalePembrolizumab+LenvatinibDocetaxel
Change From Baseline in European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Combined Global Health Status / Quality of Life (Items 29 & 30) Scale Combined Score-2.48 (-5.44 to 0.49)-1.12 (-4.22 to 1.98)
Statistical analysis
  • Pembrolizumab+Lenvatinib vs Docetaxel · t-test, 2 sided · p = 0.4998 · Difference in least squares means: -1.36 · 95% CI -5.32 to 2.60Based on cLDA model with covariates for treatment by time interaction, stratification factors of baseline ECOG performance status, anti-PD-1/PD-L1 mAb therapy, and baseline PD-L1 Status
SecondaryChange From Baseline in EORTC Quality of Life Questionnaire Lung Cancer Module 13 (QLQ-LC13) Cough (Item 31) Scale Score

Used in combination with QLQ-C30, the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, including a single-item scale score for cough (Item 31). For this item, individual responses to the question "How much did you cough?" are given on a 4-point scale (1=Not at all; 4=Very much). Scores are transformed to a range from 0-100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-LC13 cough (Item 31) scale score is presented.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer Module 13 (QLQ-LC13) Cough (Item 31) Scale Score
Scores on a scalePembrolizumab+LenvatinibDocetaxel
Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer Module 13 (QLQ-LC13) Cough (Item 31) Scale Score-4.17 (-8.08 to -0.27)-0.32 (-4.40 to 3.77)
Statistical analysis
  • Pembrolizumab+Lenvatinib vs Docetaxel · t-test, 2 sided · p = 0.1531 · Difference in least squares mean: -3.86 · 95% CI -9.16 to 1.44Based on cLDA model with covariates for treatment by time interaction, stratification factors of baseline ECOG performance status, anti-PD-1/PD-L1 mAb therapy, and baseline PD-L1 Status
SecondaryChange From Baseline in EORTC QLQ-LC13 Chest Pain (Item 40) Scale Score

Used in combination with QLQ-C30, the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, including a single-item scale score for chest pain (Item 40). For this item, individual responses to the question "Have you had pain in your chest?" are given on a 4-point scale (1=Not at all; 4=Very much). Scores are transformed to a range from 0-100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-LC13 chest pain (Item 40) scale score is presented.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in EORTC QLQ-LC13 Chest Pain (Item 40) Scale Score
Scores on a scalePembrolizumab+LenvatinibDocetaxel
Change From Baseline in EORTC QLQ-LC13 Chest Pain (Item 40) Scale Score-1.40 (-4.92 to 2.12)-3.88 (-7.58 to -0.18)
Statistical analysis
  • Pembrolizumab+Lenvatinib vs Docetaxel · t-test, 2 sided · p = 0.3084 · Difference in least squares means: 2.48 · 95% CI -2.31 to 7.27Based on cLDA model with covariates for treatment by time interaction, stratification factors of baseline ECOG performance status, timing of anti-PD-1/PD-L1 mAb therapy, and baseline PD-L1 Status
SecondaryChange From Baseline in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score

The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a single-item scale score for dyspnea (Item 8). For this item, individual responses to the question "Were you short of breath?" are given on a 4-point scale (1=Not at all; 4=Very much). Scores are transformed to a range from 0-100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-C30 dyspnea (Item 8) scale score is presented.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score
Scores on a scalePembrolizumab+LenvatinibDocetaxel
Change From Baseline in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score-2.92 (-7.08 to 1.23)5.12 (0.79 to 9.45)
Statistical analysis
  • Pembrolizumab+Lenvatinib vs Docetaxel · t-test, 2 sided · p = 0.0058 · Difference in least squares means: -8.04 · 95% CI -13.73 to -2.35Based on cLDA model with covariates for treatment by time interaction, stratification factors of baseline ECOG performance status, anti-PD-1/PD-L1 mAb therapy, and baseline PD-L1 Status
SecondaryChange From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Combined Score

The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a physical functioning (PF) scale (Items 1 to 5). The PF scale consists of participant responses to 5 questions regarding performance of daily activities \[1) strenuous activities; 2) long walks; 3) short walks; 4) bed/chair rest; and 5) needing help with eating, dressing, washing themselves or using the toilet\]. Overall PF scores range from 0 to 100, with a lower score indicating a better outcome. The change from Baseline in the EORTC QLQ-C30 PF (Items 1 to 5) scale combined score is presented.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Combined Score
Scores on a scalePembrolizumab+LenvatinibDocetaxel
Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Combined Score-5.58 (-8.51 to -2.65)-8.47 (-11.51 to -5.43)
Statistical analysis
  • Pembrolizumab+Lenvatinib vs Docetaxel · t-test, 2 sided · p = 0.1681 · Difference in least squares means: 2.89 · 95% CI -1.23 to 7.01Based on cLDA model with covariates for treatment by time interaction, stratification factors of baseline ECOG performance status, anti-PD-1/PD-L1 mAb therapy, and baseline PD-L1 Status
SecondaryTime to True Deterioration (TTD) in EORTC QLQ-C30 Combined Global Health Status / Quality of Life (Items 29 & 30) Scale Combined Score

The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a combined GHS/QoL (Items 29 and 30) scale. The TTD in the combined GHS/QoL (Items 29 \& 30) scale combined score is presented, defined as the time to first onset of a ≥10 point decrease from baseline. A longer TTD indicates a better outcome

Time frame:
Up to 24 months
Reported as:
Median · Months
Time to True Deterioration (TTD) in EORTC QLQ-C30 Combined Global Health Status / Quality of Life (Items 29 & 30) Scale Combined Score
MonthsPembrolizumab+LenvatinibDocetaxel
Time to True Deterioration (TTD) in EORTC QLQ-C30 Combined Global Health Status / Quality of Life (Items 29 & 30) Scale Combined Score8.51 (6.24 to NA)9.59 (5.78 to NA)
Statistical analysis
  • Pembrolizumab+Lenvatinib vs Docetaxel · Log Rank · p = 0.6145 (stratified by Baseline ECOG performance status, anti-PD-1/PD-L1 mAb therapy, and Baseline PD-L1 Status.) · Hazard ratio (hr): 0.91 · 95% CI 0.63 to 1.31Based on stratified Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Baseline ECOG performance status, anti-PD-1/PD-L1 mAb therapy, and Baseline PD-L1 Status.
SecondaryTime to True Deterioration (TTD) in EORTC QLQ-LC13 Cough (Item 31) Scale Score

Used in combination with QLQ-C30, the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, including a single-item scale score for cough (Item 31). The TTD in EORTC QLQ-LC13 cough (Item 31) scale score is presented, defined as the time to first onset of a ≥10 point decrease from baseline.

Time frame:
Up to ~24 months
Reported as:
Median · Months
Time to True Deterioration (TTD) in EORTC QLQ-LC13 Cough (Item 31) Scale Score
MonthsPembrolizumab+LenvatinibDocetaxel
Time to True Deterioration (TTD) in EORTC QLQ-LC13 Cough (Item 31) Scale ScoreNA (NA to NA)NA (10.97 to NA)
Statistical analysis
  • Pembrolizumab+Lenvatinib vs Docetaxel · Log Rank · p = 0.0398 · Hazard ratio (hr): 0.61 · 95% CI 0.38 to 0.98Based on stratified Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Baseline ECOG performance status, anti-PD-1/PD-L1 mAb therapy, and Baseline PD-L1 Status.
SecondaryTime to True Deterioration (TTD) in EORTC QLQ-LC13 Chest Pain (Item 40) Scale Score

Used in combination with QLQ-C30, the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, including a single-item scale score for chest pain (Item 40). The TTD in EORTC QLQ-LC13 chest pain (Item 40) scale score is presented, defined as the time to first onset of a ≥10 point decrease from baseline.

Time frame:
Up to ~24 months
Reported as:
Median · Months
Time to True Deterioration (TTD) in EORTC QLQ-LC13 Chest Pain (Item 40) Scale Score
MonthsPembrolizumab+LenvatinibDocetaxel
Time to True Deterioration (TTD) in EORTC QLQ-LC13 Chest Pain (Item 40) Scale ScoreNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab+Lenvatinib vs Docetaxel · Log Rank · p = 0.8724 · Hazard ratio (hr): 1.05 · 95% CI 0.59 to 1.85Based on stratified Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Baseline ECOG performance status, anti-PD-1/PD-L1 mAb therapy, and Baseline PD-L1 Status
SecondaryTime to True Deterioration (TTD) in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score

The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a single-item scale score for dyspnea (Item 8). The TTD in dyspnea (Item 8) scale score will be presented, defined as the time to first onset of a ≥10 point decrease from baseline.

Time frame:
Up to ~24 months
Reported as:
Median · Months
Time to True Deterioration (TTD) in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score
MonthsPembrolizumab+LenvatinibDocetaxel
Time to True Deterioration (TTD) in EORTC QLQ-C30 Dyspnea (Item 8) Scale ScoreNA (NA to NA)NA (10.84 to NA)
Statistical analysis
  • Pembrolizumab+Lenvatinib vs Docetaxel · Log Rank · p = 0.1944 (Stratified by Baseline ECOG performance status, anti-PD-1/PD-L1 mAb therapy, and Baseline PD-L1 Status.) · Hazard ratio (hr): 0.75 · 95% CI 0.49 to 1.16Based on stratified Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Baseline ECOG performance status, anti-PD-1/PD-L1 mAb therapy, and Baseline PD-L1 Status.
SecondaryTime to True Deterioration (TTD) in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Combined Score

The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a physical functioning (PF) scale (Items 1 to 5). The TTD in PF (Items 1 to 5) scale combined score is presented, defined as the time to first onset of a ≥10 point decrease from baseline.

Time frame:
Up to ~24 months
Reported as:
Median · Months
Time to True Deterioration (TTD) in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Combined Score
MonthsPembrolizumab+LenvatinibDocetaxel
Time to True Deterioration (TTD) in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Combined Score6.70 (5.36 to 9.86)7.03 (4.76 to NA)
Statistical analysis
  • Pembrolizumab+Lenvatinib vs Docetaxel · Log Rank · p = 0.9837 · Hazard ratio (hr): 1.00 · 95% CI 0.71 to 1.41Based on stratified Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Baseline ECOG performance status, anti-PD-1/PD-L1 mAb therapy, and Baseline PD-L1 Status.
SecondaryTime to True Deterioration (TTD) in EORTC Composite Symptom Score for Cough (QLQ-LC13 Item 31), Chest Pain (QLQ-LC13 Item 40), or Dyspnea (QLQ-C30 Item 8)

EORTC QLQ-C30 includes a single-item scale score for dyspnea (Item 8), the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, which includes a single-item scale score for cough (Item 31) and chest pain (Item 40). Time to True Deterioration for the Composite Endpoint of EORTC QLQ- LC13 Cough, EORTC QLQ- LC13 Chest Pain, or EORTC QLQ-C30 Dyspnea is presented, defined as the time to first onset of a ≥10-point decrease from baseline in any one of 3 scale items with confirmation by the subsequent visit of a 10 or more-point deterioration from baseline in the same scale as the first onset under right-censoring rule.

Time frame:
Up to ~ 24 months
Reported as:
Median · Months
Time to True Deterioration (TTD) in EORTC Composite Symptom Score for Cough (QLQ-LC13 Item 31), Chest Pain (QLQ-LC13 Item 40), or Dyspnea (QLQ-C30 Item 8)
MonthsPembrolizumab+LenvatinibDocetaxel
Time to True Deterioration (TTD) in EORTC Composite Symptom Score for Cough (QLQ-LC13 Item 31), Chest Pain (QLQ-LC13 Item 40), or Dyspnea (QLQ-C30 Item 8)9.20 (5.59 to 12.62)5.55 (3.48 to 12.78)
Statistical analysis
  • Pembrolizumab+Lenvatinib vs Docetaxel · Log Rank · p = 0.2903 · Hazard ratio (hr): 0.84 · 95% CI 0.60 to 1.16Based on stratified Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Baseline ECOG performance status, anti-PD-1/PD-L1 mAb therapy, and Baseline PD-L1 Status.

Adverse events

Collected over Up to approximately 59 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab + Lenvatinib161/185 (87%)99/181 (54.7%)170/181 (93.9%)
Docetaxel164/189 (86.8%)66/177 (37.3%)165/177 (93.2%)
Lenvatinib46/48 (95.8%)28/47 (59.6%)45/47 (95.7%)
Most frequent serious events
Showing 10 of 161
Most frequent serious events
EventPembrolizumab + LenvatinibDocetaxelLenvatinib
Cardiac arrestCardiac disorders2/1812/1773/47
Lower respiratory tract infectionInfections and infestations2/1811/1773/47
PneumoniaInfections and infestations10/1819/1772/47
Febrile neutropeniaBlood and lymphatic system disorders0/1818/1770/47
Pulmonary embolismRespiratory, thoracic and mediastinal disorders6/1812/1772/47
Hypertensive crisisVascular disorders0/1810/1772/47
DiarrhoeaGastrointestinal disorders7/1812/1770/47
Neutropenic sepsisInfections and infestations0/1814/1770/47
ColitisGastrointestinal disorders4/1811/1770/47
HyponatraemiaMetabolism and nutrition disorders4/1810/1770/47
Most frequent other events
Showing 10 of 64
Most frequent other events
EventPembrolizumab + LenvatinibDocetaxelLenvatinib
HypertensionVascular disorders75/1816/17724/47
DiarrhoeaGastrointestinal disorders74/18135/17718/47
HypothyroidismEndocrine disorders64/1813/17717/47
NauseaGastrointestinal disorders40/18133/17716/47
FatigueGeneral disorders42/18138/17716/47
Decreased appetiteMetabolism and nutrition disorders57/18136/17713/47
AnaemiaBlood and lymphatic system disorders23/18150/1772/47
AstheniaGeneral disorders50/18147/17712/47
AlopeciaSkin and subcutaneous tissue disorders3/18146/1770/47
ConstipationGastrointestinal disorders27/18116/17712/47

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pembrolizumab+LenvatinibDocetaxelLenvatinibTotal
Mean64.2 ± 8.364.3 ± 9.564.0 ± 7.264.2 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab+LenvatinibDocetaxelLenvatinibTotal
Female676019146
Male11812929276
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab+LenvatinibDocetaxelLenvatinibTotal
Hispanic or Latino1212428
Not Hispanic or Latino16016040360
Unknown or Not Reported1317434
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab+LenvatinibDocetaxelLenvatinibTotal
American Indian or Alaska Native3205
Asian2232862
Native Hawaiian or Other Pacific Islander0000
Black or African American2305
White14613535316
More than one race1214
Unknown or Not Reported1115430
Eastern Cooperative Oncology Group (ECOG) at baseline
Eastern Cooperative Oncology Group (ECOG) at baseline(Participants)Pembrolizumab+LenvatinibDocetaxelLenvatinibTotal
ECOG 0676717151
ECOG 111812231271
Sequence of Prior Anti-programmed cell death protein 1 (PD-1)/PD-L1 Therapy
Sequence of Prior Anti-programmed cell death protein 1 (PD-1)/PD-L1 Therapy(Participants)Pembrolizumab+LenvatinibDocetaxelLenvatinibTotal
Immediate Prior Therapy -Anti-PD-1/PD-L114515038333
Not Immediate Prior Therapy--Anti-PD-1/PD-L140391089
Programmed cell death ligand 1 (PD-L1)Status
Programmed cell death ligand 1 (PD-L1)Status(Participants)Pembrolizumab+LenvatinibDocetaxelLenvatinibTotal
TPS<50%13514034309
TPS>=50%34331077
Unknown1616436
08

Study locations

143 sites
  • Comprehensive Blood & Cancer Center [Bakersfield, CA] ( Site 1604)
    Bakersfield, California 93309, United States
  • Cancer Specialists of North Florida - Fleming Island ( Site 1675)
    Fleming Island, Florida 32003, United States
  • Mid-Florida Cancer Centers ( Site 1611)
    Orange City, Florida 32763, United States
  • University of Kentucky School of Medicine & Hospitals ( Site 1621)
    Lexington, Kentucky 40536, United States
  • Hematology Oncology Clinic ( Site 1680)
    Baton Rouge, Louisiana 70809, United States
  • Harry & Jeanette Weinberg Cancer Institute ( Site 1626)
    Baltimore, Maryland 21237, United States
  • Medstar Good Samaritan Hospital ( Site 1625)
    Baltimore, Maryland 21239, United States
  • Massachusetts General Hospital ( Site 1622)
    Boston, Massachusetts 02114, United States
  • MGH - North Shore Cancer Center ( Site 1668)
    Danvers, Massachusetts 01923, United States
  • The Mass General Cancer Center at Newton-Wellesley ( Site 1692)
    Newton, Massachusetts 02462, United States
  • University of Massachusetts Medical School ( Site 1693)
    Worcester, Massachusetts 01655, United States
  • Billings Clinic ( Site 1631)
    Billings, Montana 59101, United States
  • Bozeman Health Deaconness Cancer Center ( Site 1632)
    Bozeman, Montana 59715, United States
  • Memorial Sloan-Kettering Cancer Center At Basking Ridge ( Site 1664)
    Basking Ridge, New Jersey 07920, United States
  • Memorial Sloan-Kettering Cancer Center at Middletown ( Site 1665)
    Middletown, New Jersey 07748, United States
  • Memorial Sloan-Kettering Cancer Center at Montvale ( Site 1667)
    Montvale, New Jersey 07645, United States
  • Memorial Sloan-Kettering Cancer Center at Commack ( Site 1662)
    Commack, New York 11725, United States
  • Memorial Sloan-Kettering Cancer Center at West Harrison ( Site 1666)
    Harrison, New York 10604, United States
  • Memorial Sloan-Kettering Cancer Center ( Site 1661)
    New York, New York 10065, United States
  • New York Cancer and Blood Specialists ( Site 1696)
    Port Jefferson Station, New York 11776, United States
  • University of Rochester ( Site 1638)
    Rochester, New York 14642, United States
  • Memorial Sloan Kettering Cancer Center - Nassau ( Site 1670)
    Uniondale, New York 11553, United States
  • TriHealth Cancer Institute ( Site 1672)
    Cincinnati, Ohio 45220, United States
  • MetroHealth Medical Center ( Site 1694)
    Cleveland, Ohio 44109, United States
  • Kaiser Permanente Center for Health Research-Kaiser Permanente Medical Center ( Site 1644)
    Portland, Oregon 97227, United States
  • Fox Chase Cancer Center ( Site 1647)
    Philadelphia, Pennsylvania 19111, United States
  • Thompson Cancer Survival Center ( Site 1695)
    Knoxville, Tennessee 37916, United States
  • Millenium Physicians ( Site 1690)
    Houston, Texas 77090, United States
  • Instituto de Investigaciones Metabolicas ( Site 2004)
    Caba, Buenos Aires C1012AAR, Argentina
  • Hospital Britanico de Buenos Aires ( Site 2002)
    Buenos Aires, Buenos Aires F.D. C1280AEB, Argentina
  • Sanatorio Parque ( Site 2005)
    Rosario, Santa Fe Province S2000DSV, Argentina
  • Hospital Aleman ( Site 2000)
    Buenos Aires, C1118AAT, Argentina
  • CEMIC ( Site 2003)
    Buenos Aires, C1431FWO, Argentina
  • Blacktown Hospital ( Site 0004)
    Blacktown, New South Wales 2148, Australia
  • Port Macquarie Base Hospital ( Site 0003)
    Port Macquarie, New South Wales 2444, Australia
  • Westmead Hospital ( Site 0005)
    Westmead, New South Wales 2145, Australia
  • Southern Medical Day Care Centre ( Site 0001)
    Wollongong, New South Wales 2500, Australia
  • Princess Alexandra Hospital - Division of Cancer Services ( Site 0002)
    Woolloongabba, Queensland 4102, Australia
  • Calvary Central Districts Hospital ( Site 0007)
    Elizabeth Vale, South Australia 5112, Australia
  • Bendigo Cancer Centre ( Site 0008)
    Bendigo, Victoria 3552, Australia
  • CancerCare Manitoba ( Site 1504)
    Winnipeg, Manitoba R3E 0V9, Canada
  • Kingston Health Sciences Centre ( Site 1503)
    Kingston, Ontario K7L 2V7, Canada
  • London Regional Cancer Program - London HSC ( Site 1505)
    London, Ontario N6A 5W9, Canada
  • Princess Margaret Cancer Centre ( Site 1502)
    Toronto, Ontario M5G 2M9, Canada
  • CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 1501)
    Montreal, Quebec H3T 1M5, Canada
  • CHUQ-Univ Laval-Hotel Dieu de Quebec ( Site 1514)
    Québec, Quebec G1R 2J6, Canada
  • Rodrigo Botero SAS ( Site 1300)
    Medellín, Antioquia 050030, Colombia
  • Clinica de la Costa Ltda. ( Site 1309)
    Barranquilla, Atlántico 080020, Colombia
  • Administradora Country SA - Clinica del Country ( Site 1307)
    Bogotá, Bogota D.C. 110221, Colombia
  • Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 1304)
    Bogotá, Bogota D.C. 110311, Colombia
  • Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 1305)
    Valledupar, Cesar Department 200001, Colombia
  • Oncomedica S.A. ( Site 1302)
    Montería, Departamento de Córdoba 230001, Colombia
  • Centro Medico Imbanaco de Cali S.A ( Site 1301)
    Cali, Valle del Cauca Department 760042, Colombia
  • CHU Caen Service de Pneumologie ( Site 0401)
    Caen, Calvados 14033, France
  • HIA Percy-Clamart ( Site 0411)
    Clamart, Hauts-de-Seine 92140, France
  • ICO Centre Paul Papin ( Site 0412)
    Angers, Maine-et-Loire 49100, France
  • Clinique Ambroise Pare ( Site 0402)
    Beuvry, Pas-de-Calais 62660, France
  • Centre Hospitalier General - Avignon ( Site 0407)
    Avignon, Provence-Alpes-Côte d'Azur Region 84000, France
  • Centre Hospitalier Le Mans ( Site 0406)
    Le Mans, Sarthe 72037, France
  • Institut Curie ( Site 0400)
    Paris, 75005, France
  • Hopital Europeen Georges Pompidou ( Site 0408)
    Paris, 75015, France
  • Thoraxklinik Heidelberg gGmbH am Universitaetsklinikum Heidelberg ( Site 0501)
    Heidelberg, Baden-Wurttemberg 69126, Germany
  • Evangelisches Krankenhaus Hamm gGmbH ( Site 0504)
    Hamm, North Rhine-Westphalia 59063, Germany
  • SRH Wald-Klinikum Gera GmbH ( Site 0503)
    Gera, Thuringia 07548, Germany
  • Vivantes Klinikum Spandau ( Site 0505)
    Berlin, 13585, Germany
  • General Hospital of Chest Diseases "Sotiria" ( Site 1703)
    Athens, Attica 115 27, Greece
  • Metropolitan Hospital-4th Oncology Dept ( Site 1700)
    Athens, Attica 185 47, Greece
  • University Hospital of Ioannina ( Site 1701)
    Ioannina, 455 00, Greece
  • European Interbalkan Medical Center ( Site 1704)
    Thessaloniki, 570 01, Greece
  • Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház ( Site 0601)
    Miskolc, Borsod-Abauj Zemplen county 3526, Hungary
  • Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz ( Site 0606)
    Székesfehérvár, Fejér 8000, Hungary
  • Petz Aladar Megyei Oktato Korhaz ( Site 0609)
    Győr, Győr-Moson-Sopron 9024, Hungary
  • Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 0610)
    Szolnok, Jász-Nagykun-Szolnok 5004, Hungary
  • Tudogyogyintezet Torokbalint ( Site 0602)
    Törökbálint, Pest County 2045, Hungary
  • Veszprem Megyei Tudogyogyintezet ( Site 0607)
    Farkasgyepű, Veszprém megye 8582, Hungary
  • Semmelweis Egyetem.. ( Site 0604)
    Budapest, 1083, Hungary
  • Orszagos Koranyi Pulmonologiai Intezet ( Site 0603)
    Budapest, 1121, Hungary
  • Orszagos Koranyi Pulmonologiai Intezet ( Site 0608)
    Budapest, 1121, Hungary
  • Soroka Medical Center ( Site 0701)
    Beersheba, 8410101, Israel
  • Rambam Medical Center ( Site 0703)
    Haifa, 3525408, Israel
  • Shaare Zedek Medical Center-Oncology ( Site 0706)
    Jerusalem, 9013102, Israel
  • Meir Medical Center ( Site 0702)
    Kfar Saba, 4428132, Israel
  • Rabin Medical Center ( Site 0700)
    Petah Tikva, 4941492, Israel
  • Chaim Sheba Medical Center ( Site 0704)
    Ramat Gan, 5262000, Israel
  • Sourasky Medical Center (Ichilov) - Oncology Clinic ( Site 0705)
    Tel Aviv, 6423906, Israel
  • Ospedale San Gerardo - ASST Monza ( Site 0804)
    Monza, Monza E Brianza 20900, Italy
  • Istittuto Nazionale dei Tumori Regina Elena IRCCS - IFO ( Site 0807)
    Rome, Roma 00144, Italy
  • A.O. Ospedali Riuniti Villa Sofia - Cervello P.O. Villa Sofia ( Site 0810)
    Palermo, Sicily 90146, Italy
  • Ospedale San Luigi Gonzaga ( Site 0802)
    Orbassano, Torino 10043, Italy
  • Azienda Ospedaliera San Giuseppe Moscati ( Site 0809)
    Avellino, 83100, Italy
  • IRCCS Giovanni Paolo II. Ospedale Oncologico ( Site 0808)
    Bari, 70124, Italy
  • AOU Policlinico Vittorio Emanuele ( Site 0811)
    Catania, 95123, Italy
  • Istituto Nazionale dei Tumori ( Site 0806)
    Milan, 20133, Italy
  • Policlinico San Matteo - Fondazione IRCCS ( Site 0812)
    Pavia, 27100, Italy
  • Azienda Ospedaliera di Perugia ( Site 0805)
    Perugia, 06132, Italy
  • Kanagawa Cardiovascular and Respiratory Center ( Site 0105)
    Yokohama, Kanagawa 236-0051, Japan
  • Sendai Kousei Hospital ( Site 0107)
    Sendai, Miyagi 980-0873, Japan
  • Kansai Medical University Hospital ( Site 0104)
    Hirakata, Osaka 573-1191, Japan
  • Chiba University Hospital ( Site 0106)
    Chiba, 260-8677, Japan
  • Niigata Cancer Center Hospital ( Site 0101)
    Niigata, 951-8566, Japan

Showing the first 100 of 143 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Leighl NB, Paz-Ares L, Abreu DR, Hui R, Baka S, Bigot F, Nishio M, Smolin A, Ahmed S, Schoenfeld AJ, Daher S, Cortinovis DL, Di Noia V, Linardou H, Gainor JF, Dutcus C, Okpara CE, Deng X, Kush D, Arunachalam A, Song A, Cho BC. LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy. J Thorac Oncol. 2025 Oct;20(10):1489-1504. doi: 10.1016/j.jtho.2025.05.020. Epub 2025 Jun 3. PubMed 40473109 ↗
  • Xing P, Wang M, Zhao J, Zhong W, Chi Y, Xu Z, Li J. Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy. Thorac Cancer. 2021 Oct;12(20):2825-2828. doi: 10.1111/1759-7714.14113. Epub 2021 Aug 18. PubMed 34409776 ↗
  • Taylor MH, Schmidt EV, Dutcus C, Pinheiro EM, Funahashi Y, Lubiniecki G, Rasco D. The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. Future Oncol. 2021 Feb;17(6):637-648. doi: 10.2217/fon-2020-0937. Epub 2020 Dec 10. PubMed 33300372 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Aug 2023, 49 months.

Results were first posted in Aug 2024, 1 year after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 49 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2019
First posted
Jun 6, 2019
StartActual
Jun 26, 2019
Primary completionActual
Aug 11, 2023
CompletionActual
Aug 22, 2024
Results first posted
Aug 22, 2024
Last update
Aug 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03976375
Collaborators
Eisai Inc.
Responsible party
Sponsor
First posted
Jun 6, 2019
Start date
Jun 26, 2019
Primary completion
Aug 11, 2023
Completion
Aug 22, 2024
Results posted
Aug 22, 2024
Last update
Aug 15, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pembrolizumab · Lenvatinib

Start the discussion